ReviewThe FEBS journal2025
Exploring the human archaeome: its relevance for health and disease, and its complex interplay with the human immune system.
Review in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial.Nature communications · 2026Trial
- DELTA: Strengthening human biological resilience with an N=1 digital health and dynamic biomarker protocol.PloS one · 2026Trial
- Neglected kingdoms: the gut virome, mycobiome and their role in inflammatory bowel disease.Gut microbes · 2026Review
- Colonic nutritional and physicochemical parameters drive gut microbiota dysbiosis in obesity: what we learned from the Ob-M-ARCOL model development.Gut microbes · 2026Article
- Methanogens: vital but threatened members of the human microbiome?Trends in microbiology · 2026Review
- Review
- Mass spectrometry-based metabolomics approaches to interrogate host-microbiome interactions in mammalian systems.Natural product reports · 2026Review
- Immune surveillance and microbial escape in the aging host: Why does the microbiome lose its balance?PLoS biology · 2026Review
- The naked mole-rat microbiome is associated with healthy aging and social structure.Cell reports · 2026Article
- Cross-domain metabolic interactions link Methanobrevibacter smithii to colorectal cancer microbial ecosystems.Nature communications · 2026Article
- Human gut archaea collection from Estonian population.Scientific data · 2026Article
- Crosstalk between the microbiome and the mucosal immunoglobulin A system in the lung, in health and disease.Frontiers in cellular and infection microbiology · 2026Review
- Host-pathogen interactions in periodontitis: an integrative interkingdom perspective.Frontiers in immunology · 2026Review
- The Human Archaeome: Commensals, Opportunists, or Emerging Pathogens?Pathogens (Basel, Switzerland) · 2025Review
- Proteomic and metabolomic profiling of extracellular vesicles produced by human gut archaea.Nature communications · 2025Article
- Immunotoxicity Study of Cucurbit[n]urils (n = 6, 7, 8) and Modeling of Interaction with Some Monocyte Receptors by a Molecular Docking Method.Molecules (Basel, Switzerland) · 2025Article
- Reevaluation of the gastrointestinal methanogenic archaeome in multiple sclerosis and its association with treatment.Microbiology spectrum · 2025Article
- Advancing archaeal research through FAIR resource and data sharing, and inclusive community building.Communications biology · 2025Review
- Longitudinal and Multi-Kingdom Gut Microbiome Alterations in a Mouse Model of Alzheimer's Disease.International journal of molecular sciences · 2024Article
- Targeted isolation of Methanobrevibacter strains from fecal samples expands the cultivated human archaeome.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
This Review aims to coalesce existing knowledge on the human archaeome, a less-studied yet critical non-bacterial component of the human microbiome, with a focus on its interaction with the immune system. Despite a largely bacteria-centric focus in microbiome research, archaea present unique challenges and opportunities for understanding human health. We examine the archaeal distribution across different human body sites, such as the lower gastrointestinal tract (LGT), upper aerodigestive tract (UAT), urogenital tract (UGT), and skin. Variability in archaeal composition exists between sites; methanogens dominate the LGT, while Nitrososphaeria are prevalent on the skin and UAT. Archaea have yet to be classified as pathogens but show associations with conditions such as refractory sinusitis and vaginosis. In the LGT, methanogenic archaea play critical metabolic roles by converting bacterial end-products into methane, correlating with various health conditions, including obesity and certain cancers. Finally, this work looks at the complex interactions between archaea and the human immune system at the molecular level. Recent research has illuminated the roles of specific archaeal molecules, such as RNA and glycerolipids, in stimulating immune responses via innate immune receptors like Toll-like receptor 8 (TLR8) and 'C-type lectin domain family 4 member E' (CLEC4E; also known as MINCLE). Additionally, metabolic by-products of archaea, specifically methane, have demonstrated immunomodulatory effects through anti-inflammatory and anti-oxidative pathways. Despite these advancements, the mechanistic underpinnings of how archaea influence immune activity remain a fertile area for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.